Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia

Read post on prnewswire.com

SHANGHAI, Oct. 17, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta Bio"), a company spun out of the in vivo CAR-T platform of Beijing Grit Biotherapeutics Co., Ltd. ("Grit Bio"), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan...